E-LIB Suche - Ergebnisse für: Banerji, U.

1

78P Implementing the modified partial order time-to-event c..:

Hu, X. ; Banerji, U. ; Yap, C.
ESMO Open. 9 (2024) - p. 102306 , 2024

Link: https://doi.org/10.1016/..

2

A first-in-human phase I study of the PD-1 inhibitor, retif..:

Lakhani, N. ; Cosman, R. ; Banerji, U....
ESMO Open. 9 (2024) 4 - p. 102254 , 2024

Link: https://doi.org/10.1016/..

3

134P A phase I study exploring the safety and tolerability ..:

Pinato, D.J. ; Banerji, U. ; Rottey, S....
Immuno-Oncology and Technology. 20 (2023) - p. 100606 , 2023

Link: https://doi.org/10.1016/..

4

The paradox-breaking panRAF plus SRC family kinase inhibito..:

Saturno, G. ; Lopes, F. ; Niculescu-Duvaz, I....
Annals of Oncology. 32 (2021) 2 - p. 269-278 , 2021

Link: https://doi.org/10.1016/..

5

A phase I dose-escalation study of enzalutamide in combinat..:

Kolinsky, M.P. ; Rescigno, P. ; Bianchini, D....
Annals of Oncology. 31 (2020) 5 - p. 619-625 , 2020

Link: https://doi.org/10.1016/..

6

PO-498 Quantifying the dynamics of acquired treatment resis..:

Acar, A. ; Nichol, D. ; Thavasu, P....
ESMO Open. 3 (2018) - p. A217 , 2018

Link: https://doi.org/10.1136/..

7

PATRIOT: A phase I study to assess the tolerability, safety..:

Dillon, M.T. ; Boylan, Z. ; Smith, D....
Clinical and Translational Radiation Oncology. 12 (2018) - p. 16-20 , 2018

Link: https://doi.org/10.1016/..

8

Vistusertib (dual m-TORC1/2 inhibitor) in combination with ..:

Basu, B. ; Krebs, M.G. ; Sundar, R....
Annals of Oncology. 29 (2018) 9 - p. 1918-1925 , 2018

Link: https://doi.org/10.1093/..

9

Clinical Outcome of Patients with Advanced Biliary Tract Ca..:

Sundar, R. ; Custodio, A. ; Petruckevich, A....
Clinical Oncology. 30 (2018) 3 - p. 185-191 , 2018

Link: https://doi.org/10.1016/..

10

A phase I/II trial of AT9283, a selective inhibitor of auro..:

Vormoor, B. ; Veal, G. J. ; Griffin, M. J....
Pediatric Blood & Cancer. 64 (2016) 6 - p. e26351 , 2016

Link: https://doi.org/10.1002/..

11

Phase I trial outcomes in older patients with advanced soli..:

Khan, K H ; Yap, T A ; Ring, A...
British Journal of Cancer. 114 (2016) 3 - p. 262-268 , 2016

Link: https://doi.org/10.1038/..

12

Titration of signalling output: insights into clinical comb..:

Stewart, A. ; Thavasu, P. ; de Bono, J.S..
Annals of Oncology. 26 (2015) 7 - p. 1504-1510 , 2015

Link: https://doi.org/10.1093/..

13

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibito..:

Geuna, E ; Roda, D ; Rafii, S...
British Journal of Cancer. 113 (2015) 11 - p. 1541-1547 , 2015

Link: https://doi.org/10.1038/..

14

339 Clinical outcome and prognostic factors of patients (pt..:

Papadatos-Pastos, D. ; Roda, D. ; Luken, M. De Miguel...
European Journal of Cancer. 51 (2015) - p. S67 , 2015

Link: https://doi.org/10.1016/..

15

333 Phase I dose-escalation trial with the DNA-alkylating a..:

Van Herpen, C.M. ; Banerji, U. ; Mommers, E.C....
European Journal of Cancer. 51 (2015) - p. S65 , 2015

Link: https://doi.org/10.1016/..